This page lists the SEC filings reported by Novo Holdings A/S.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2020-10-05 | Novo Holdings A/S | Inozyme Pharma, Inc. | 2,569,379 | 11.0% | EDGAR |
| SC 13D/A | 2020-10-05 | Novo Holdings A/S | Verona Pharma plc | 22,639,667 | 5.4% | EDGAR |
| SC 13G/A | 2020-09-04 | Novo Holdings A/S | Harmony Biosciences Holdings, Inc. | 3,754,973 | 6.6% | EDGAR |
| SC 13G | 2020-08-25 | Novo Holdings A/S | Harmony Biosciences Holdings, Inc. | 4,409,803 | 6.9% | EDGAR |
| SC 13G | 2020-08-14 | Novo Holdings A/S | Freeline Therapeutics Holdings plc | 2,361,229 | 6.8% | EDGAR |
| SC 13D | 2020-08-13 | Novo Holdings A/S | Checkmate Pharmaceuticals, Inc. | 2,170,100 | 10.1% | EDGAR |
| SC 13G/A | 2020-08-11 | Novo Holdings A/S | Entasis Therapeutics Holdings Inc. | 1,173,896 | 4.3% | EDGAR |
| SC 13D | 2020-07-29 | Novo Holdings A/S | Inozyme Pharma, Inc. | 2,569,379 | 11.5% | EDGAR |
| SC 13D/A | 2020-07-24 | Novo Holdings A/S | Verona Pharma plc | 23,048,499 | 5.5% | EDGAR |
| SC 13D | 2020-07-16 | Novo Holdings A/S | Nkarta, Inc. | 2,793,865 | 8.6% | EDGAR |
| SC 13D/A | 2020-07-09 | Novo Holdings A/S | Corvus Pharmaceuticals, Inc. | 1,389,498 | 5.0% | EDGAR |
| SC 13G/A | 2020-06-16 | Novo Holdings A/S | Entasis Therapeutics Holdings Inc. | 2,181,843 | 8.0% | EDGAR |
| SC 13D/A | 2020-03-12 | Novo Holdings A/S | Milestone Pharmaceuticals Inc. | 2,080,885 | 8.5% | EDGAR |
| SC 13G/A | 2020-02-05 | Novo Holdings A/S | Entasis Therapeutics Holdings Inc. | 2,181,843 | 16.4% | EDGAR |
| SC 13G/A | 2020-02-05 | Novo Holdings A/S | Galera Therapeutics, Inc. | 3,409,021 | 13.7% | EDGAR |
| SC 13G/A | 2020-02-05 | Novo Holdings A/S | Inogen Inc | 3,549,320 | 16.1% | EDGAR |
| SC 13G/A | 2020-02-05 | Novo Holdings A/S | SeaSpine Holdings Corp | 1,658,037 | 6.4% | EDGAR |
| SC 13D/A | 2020-01-17 | Novo Holdings A/S | Mirum Pharmaceuticals, Inc. | 2,445,147 | 9.6% | EDGAR |
| SC 13D/A | 2019-11-27 | Novo Holdings A/S | Milestone Pharmaceuticals Inc. | 2,434,470 | 9.9% | EDGAR |
| SC 13G | 2019-11-14 | Novo Holdings A/S | Galera Therapeutics, Inc. | 3,409,021 | 14.0% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.